Symphogen Inks $632M Deal with Merck for Cancer Drug
By Nuala Moran
Thursday, September 6, 2012
LONDON – Symphogen A/S has handed Merck KGaA worldwide exclusive rights to its Phase II cancer antibody product, Sym004, in a deal with a potential value of €500 million (US$631.6 million).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.